Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

Author:

Ambrosioni Juan12ORCID,Levi Laura3,Alagaratnam Jasmini45ORCID,Van Bremen Kathrin6,Mastrangelo Andrea7,Waalewijn Hylke8ORCID,Molina Jean‐Michel3,Guaraldi Giovanni9ORCID,Winston Alan5ORCID,Boesecke Christoph6,Cinque Paola10ORCID,Bamford Alasdair11ORCID,Calmy Alexandra12,Marzolini Catia131415,Martínez Esteban12,Oprea Cristiana16ORCID,Welch Steven17,Koval Anna18,Mendao Luis19,Rockstroh Jürgen K.6,

Affiliation:

1. HIV Unit, Infectious Diseases Service, Hospital Clinic‐Fundació de recerca Clinic Barcelona – Institut de investigacions Biomediques August Pi i Sunyer Barcelona Spain

2. CIBERINFEC, Instituto de Salud Carlos III Madrid Spain

3. Department of Infectious Diseases, St‐Louis and Lariboisière Hospitals, APHP University of Paris Cité Paris France

4. HIV Medicine & Sexual Health Chelsea & Westminster Hospital NHS Foundation Trust London UK

5. Section of Virology, Department of Infectious Disease Imperial College London London UK

6. Department of Medicine I Bonn University Hospital Bonn Germany

7. Allergology and Immunology Department Centre Hopitalier Universitaire Vaudoise (CHUV) Lausanne Switzerland

8. Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa

9. Department of Surgical, Medical, Dental and Morphological Sciences University of Modena and Reggio Emilia Modena Italy

10. Unit of Infectious Diseases San Raffaele Scientific Institute Milano Italy

11. Great Ormond Street Hospital for Children NHS Foundation Trust London UK

12. HIV/AIDS Unit, Division of Infectious Diseases Geneva University Hospitals Geneva Switzerland

13. Departments of Medicine and Clinical Research University Hospital Basel and University of Basel Basel Switzerland

14. Service of Clinical Pharmacology University Hospital Lausanne and University of Lausanne Lausanne Switzerland

15. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine University of Liverpool Liverpool UK

16. Infectious Diseases and HIV Department, Victor Babes Clinical Hospital for Infectious and Tropical Diseases Carol Davila University of Medicine and Pharmacy Bucharest Romania

17. Department of Paediatrics University Hospitals Birmingham NHS Foundation Trust Birmingham UK

18. University Medical Center Hamburg‐Eppendorf Germany

19. European AIDS Treatment Group Brussels Belgium

Abstract

AbstractBackgroundThe European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.Key Points of the Guidelines UpdateVersion 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐naïve adults as versions 11.0 and 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long‐acting section has been expanded in the ART and drug–drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti‐infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient‐reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir‐free two‐drug regimens in people with isolated anti‐hepatitis B core antibodies are provided. In the opportunistic infections and COVID‐19 panel, guidance on the management of COVID‐19 in people with HIV has been updated according to the most up‐to‐date evidence, and a new section on monkeypox has been added.ConclusionsIn 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3